Similar articles

• Human prostatic cancer cells, PC3, elaborate mitogenic activity which selectively stimulates human bone cells.

  Perkel VS, Mohan S, Herring SJ, Baylink DJ, Linkhart TA. Perkel VS, et al. Cancer Res. 1990 Nov 1;50(21):6902-7. Cancer Res. 1990. PMID: 1698544
• Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer.

  Koutsilieris M, Reyes-Moreno C, Sourla A, Dimitriadou V, Choki I. Koutsilieris M, et al. Anticancer Res. 1997 May-Jun;17(3A):1461-5. Anticancer Res. 1997. PMID: 9179184 Review.
• Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases.

  Koutsilieris M, Frenette G, Lazure C, Lehoux JG, Govindan MV, Polychronakos C. Koutsilieris M, et al. Anticancer Res. 1993 Mar-Apr;13(2):481-6. Anticancer Res. 1993. PMID: 7685989
• Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma.

  Festuccia C, Teti A, Bianco P, Guerra F, Vicentini C, Tennina R, Villanova I, Sciortino G, Bologna M. Festuccia C, et al. Oncol Res. 1997;9(8):419-31. Oncol Res. 1997. PMID: 9436195
• Potential role of HBGF (FGF) and TGF-beta on prostate growth.

  Matuo Y, McKeehan WL, Yan GC, Nikolaropoulos S, Adams PS, Fukabori Y, Yamanaka H, Gaudreau J. Matuo Y, et al. Adv Exp Med Biol. 1992;324:107-14. doi: 10.1007/978-1-4615-3398-6_11. Adv Exp Med Biol. 1992. PMID: 1492611 Review.